MNOV
MediciNova, Inc.1.4800
-0.0400-2.63%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
72.74MP/E (TTM)
-Basic EPS (TTM)
-0.25Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
MediciNova posted its first revenue of $0.1 million in Q2 FY2025 ended June 30, 2025, from a new Mayo agreement supporting MN-166 ALS trials, up from zero a year ago, yet operating loss widened to $3.6 million from $3.0 million on higher R&D spend for PK and DCM studies. For the half-year, revenue hit $0.1 million while operating loss climbed to $6.8 million from $6.2 million, driven by MN-166 and MN-001 trial costs, with net loss at $6.1 million or $0.13 per share on 49 million shares. Cash burn eased to $6.1 million in operations, leaving $34.3 million in cash and equivalents, enough for at least a year. No debt weighs on the balance sheet. Cash dwindles steadily.
8-K
MediciNova secures $30M equity line
MediciNova inked a standby equity deal with Yorkville on July 30, 2025, unlocking up to $30 million in funding via optional common stock sales over 36 months. Shares price at 97% of the lowest three-day VWAP, capped at 19.99% of outstanding shares without approval, while a $375,000 commitment fee underscores the cost of this flexible lifeline. Yet dilution looms large for shareholders.
8-K
Annual meeting results
MediciNova's stockholders convened their 2025 annual meeting on June 17, electing Carolyn Beaver as Class III director with 22 million for votes against 9 million against, amid 2.3 million broker non-votes. They ratified BDO USA as auditors for the fiscal year ending December 31, 2025, with overwhelming 31 million yes votes, while approving executive compensation advisory and a three-year frequency for future say-on-pay votes. Shareholder turnout hit 70% of 49 million shares outstanding. Governance stays steady.
10-Q
Q1 FY2025 results
MediciNova posted a Q1 FY2025 operating loss of $3.2M, up slightly from $3.1M a year ago, while net loss narrowed to $2.9M from $2.8M thanks to $0.3M interest income, down from $0.4M (derived). Expenses held steady at $1.8M for R&D—led by MN-166 at $1.1M—and $1.4M for G&A, with stock-based comp rising to $0.3M from $0.2M. Cash burn eased to $3.8M from $3.9M, leaving $36.6M in cash equivalents and no debt, funding operations through May 2026. No revenue yet. Cash dwindles steadily.
BCLI
BrainStorm Cell Therapeutics In
0.58+0.03
GLMD
Galmed Pharmaceuticals Ltd.
0.98+0.01
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
MDGL
Madrigal Pharmaceuticals, Inc.
554.57-5.98
MDNAF
Medicenna Therapeutics Corp.
0.79+0.01
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
MRNA
Moderna, Inc.
29.89-0.03
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NVAX
Novavax, Inc.
6.54-0.04
NVCT
Nuvectis Pharma, Inc.
7.69+0.04